Valuation: Cocrystal Pharma, Inc.

Market Cap 13.1M 11.48M 10.61M 9.76M 18.42M 1.26B 18.71M 127M 49.74M 618M 49.18M 48.11M 2.13B P/E 2026 *
-1.39x
P/E 2027 * -1.48x
Enterprise Value 13.1M 11.48M 10.61M 9.76M 18.42M 1.26B 18.71M 127M 49.74M 618M 49.18M 48.11M 2.13B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
69.27%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week-1.03%
Current month-9.51%
1 month-4.99%
3 months-37.08%
6 months-9.51%
Current year-2.95%
1 week 0.94
Extreme 0.94
0.98
1 month 0.94
Extreme 0.94
1.08
Current year 0.86
Extreme 0.8588
2.03
1 year 0.86
Extreme 0.8588
2.67
3 years 0.86
Extreme 0.8588
3.28
5 years 0.86
Extreme 0.8588
17.88
10 years 0.86
Extreme 0.8588
201.6
Manager TitleAgeSince
Chief Executive Officer 64 03/06/2026
Chief Executive Officer 59 27/05/2021
Chief Executive Officer 66 27/05/2021
Director TitleAgeSince
Director/Board Member 89 02/01/2014
Chairman 79 27/05/2021
Director/Board Member 65 02/01/2014
Date Insider Type Main position Quantity % Market Cap.
6/3/26 A Free

Chief Executive Officer

235,000 1.7044%
2/24/26 A Buy

Director

20,000 0.1451%
2/6/26 A Buy

Director

50,000 0.3627%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-1.03%-40.99%-65.20% 13.1M
+0.21%-0.79%+56.02%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
-0.18%-0.62%+5.53%+409.46% 23.48B
+0.58%+2.20%-15.48%-14.55% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-2.97%+32.73%-33.30% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
+0.21%+0.36%+27.07%+183.04% 14.06B
Average +1.06%-2.79%+34.29%+156.37% 23.36B
Weighted average by Cap. +1.70%-2.35%+42.64%+140.27%

Financials

2026 *2027 *
Net sales - -
Net income -10.5M -9.2M -8.51M -7.82M -14.76M -1.01B -15M -102M -39.87M -495M -39.43M -38.57M -1.71B -11.5M -10.08M -9.32M -8.57M -16.17M -1.11B -16.43M -111M -43.67M -543M -43.18M -42.24M -1.87B
Net Debt - -
Logo Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Employees
10
Date Price Change Volume
20/07/26 $0.9400 -1.05% 10,067
17/07/26 $0.9500 -0.01% 12,078
16/07/26 $0.9501 -1.03% 7,680
15/07/26 $0.9600 +2.10% 32,409
14/07/26 $0.9403 -2.05% 61,485
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9500USD
Average target price
9.000USD
Spread / Average Target
+847.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COCP Stock